Breaking the Cycle: Impact of Sterically-Tailored Tetra(pyrazolyl)lutidines on the Self-Assembly of Silver(I) Complexes
作者:Tyler J. Morin、Andrew Merkel、Sergey V. Lindeman、James R. Gardinier
DOI:10.1021/ic1010538
日期:2010.9.6
5-diisopropylpyrazolyl) are described. The silver(I) complexes of these ligands were studied to ascertain the impact of pyrazolyl substitution, if any, on their binding modes and on solubility issues. In the solidstate, [Ag(pz4lut)](BF4) (1), [Ag(pz4′4lut)](BF4) (2), and [Ag(pz*4lut)](BF4) (3) give cyclic dications as a result of two ligands sandwiching two silver centers where each ligand binds the metals
A bis-heteroscorpionate Pd–Ru complex (1) is developed which shows efficient tandem Suzuki coupling/transfer hydrogenation reaction towards a broad range of substrates.
Synthesis, characterisation and biological activities of [(p-cym)RuX(pz4lut)]n+ and [{(p-cym)RuX}2(μ-pz4lut)]n+ (X = Cl, H2O and pz4lut = α,α,α′,α′-tetra(pyrazol-1-yl)-2,6-lutidine)
作者:Suman Kumar Tripathy、Raj Kiran Surada、Rajesh K. Manne、Shaikh M. Mobin、Manas Kumar Santra、Srikanta Patra
DOI:10.1039/c3dt51275d
日期:——
Mononuclear [(p-cym)RuCl(pz4lut)]Cl (1) and dinuclear [(p-cym)RuCl}2(μ-pz4lut)]Cl2 (2) complexes (p-cym = 1-isopropyl-4-methylbenzene) comprising of bis(pyrazol-1-yl)methane based heteroscorpionate ligand α,α,αâ²,αâ²-tetra(pyrazol-1-yl)-2,6-lutidine (pz4lut) have been synthesised from pz4lut ligand and dimeric precursor complex [(p-cym)RuCl(μ-Cl)]2 in methanol. The aqua derivatives [(p-cym)Ru(H2O)(pz4lut)](ClO4)2 (3) and [(p-cym)Ru(H2O)}2(μ-pz4lut)](ClO4)4 (4) are obtained from 1 and 2, respectively, via Cl/H2O exchange process in presence of appropriate equivalents of AgClO4 in methanolâwater mixture. The molecular structures of dinuclear complexes, 2 and 4 are authenticated by their single crystal X-ray structures. Cyclic voltammetry reveals negligible electronic communication between the metal centres in the ligand bridged complex 2. All four complexes have been tested for their anticancer activities in human breast (MCF7), lung (A549) and colon (HCT116) cancer cell lines. The complexes show dose dependent suppression of cell viability with moderately good IC50 values ranging from 3.5â92 μM. Experimental results have revealed that the aqua derivatives, 3 and 4 exhibit better cytotoxic effect against all those cell lines as compared to the precursor chlorido complexes, 1 and 2. Results also demonstrate that the complexes are more potent against HCT116 cells as compared to other cell lines.
Time-Resolved Spectroscopy of Photoinduced Electron Transfer in Dinuclear and Tetranuclear Fe/Co Prussian Blue Analogues
作者:Jennifer Zimara、Hendrik Stevens、Rainer Oswald、Serhiy Demeshko、Sebastian Dechert、Ricardo A. Mata、Franc Meyer、Dirk Schwarzer
DOI:10.1021/acs.inorgchem.0c03249
日期:2021.1.4
square-type complex [Co2Fe2(CN)6(tp*)2(4,4′-dtbbpy)4](PF6)2 (1) exists in two electronic states. In acetonitrile solution, at <240 K, the low temperature (LT) phase is prevalent consisting of low-spin Fe(II) and low-spin Co(III), [FeIILSCoIIILS]2. Temperature rise is the reason behind thermally-induced CTIST toward the high temperature (HT) phase consisting of low-spin Fe(III) and high-spin Co(II), [FeIIILSCoIIHS]2
飞秒IR和UV / vis泵浦-探针光谱法揭示了两个Fe / Co普鲁士蓝类似物(PBA)中光驱电荷转移诱导的自旋跃迁(CTIST)的动力学。取决于温度,已知的四核方形复合物[Co 2 Fe 2(CN)6(tp *)2(4,4'-dtbbpy)4 ](PF 6)2(1)以两种电子状态存在。在乙腈溶液中,在<240 K时,低温(LT)相普遍由低自旋Fe(II)和低自旋Co(III)组成,[Fe II LS Co III LS ] 2。温度升高是热诱导CTIST向由低自旋Fe(III)和高自旋Co(II)[Fe III LS Co II HS ] 2组成的高温(HT)相背后的原因,在> 300K。在800 nm处对LT相的间隔电荷转移(IVCT)带进行光激发,在PBA 1的一个Fe-Co边缘中引发电子转移,并产生[Fe III LS Co II LS ]中间体,该中间体通过自旋交叉( SCO)在400
[EN] RUTHENIUM COMPLEXES WITH ANTITUMORAL CHEMOTHERAPY ACTIVITIES<br/>[FR] COMPLEXES DE RUTHÉNIUM PRÉSENTANT DES ACTIVITÉS DE CHIMIOTHÉRAPIE ANTITUMORALE
申请人:UNI DEGLI STUDI CAMERINO
公开号:WO2015019296A1
公开(公告)日:2015-02-12
The present invention relates to the use of ruthenium complexes as antitumoral chemotherapy agents. The complexes according to the invention are useful in the treatment of patients with solid metastatic tumours which are very often resistant to the most commonly used antitumoral drugs. The complexes according to the invention exhibit fewer side effects for the host than those developed by other metal-based chemotherapy agents.